Cargando…
Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
The ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The form...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667020/ https://www.ncbi.nlm.nih.gov/pubmed/34903717 http://dx.doi.org/10.1038/s41419-021-04420-1 |
_version_ | 1784614315629740032 |
---|---|
author | Soriano-Teruel, Paula M. García‑Laínez, Guillermo Marco-Salvador, María Pardo, Julián Arias, Maykel DeFord, Christian Merfort, Irmgard Vicent, María J. Pelegrín, Pablo Sancho, Mónica Orzáez, Mar |
author_facet | Soriano-Teruel, Paula M. García‑Laínez, Guillermo Marco-Salvador, María Pardo, Julián Arias, Maykel DeFord, Christian Merfort, Irmgard Vicent, María J. Pelegrín, Pablo Sancho, Mónica Orzáez, Mar |
author_sort | Soriano-Teruel, Paula M. |
collection | PubMed |
description | The ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The formation of ASC specks, initiated by different inflammasome receptors, promotes the recruitment and activation of procaspase-1, thereby triggering pyroptotic inflammatory cell death and pro-inflammatory cytokine release. Here we describe MM01 as the first-in-class small-molecule inhibitor of ASC that interferes with ASC speck formation. MM01 inhibition of ASC oligomerization prevents activation of procaspase-1 in vitro and inhibits the activation of different ASC-dependent inflammasomes in cell lines and primary cultures. Furthermore, MM01 inhibits inflammation in vivo in a mouse model of inflammasome-induced peritonitis. Overall, we highlight MM01 as a novel broad-spectrum inflammasome inhibitor for the potential treatment of multifactorial diseases involving the dysregulation of multiple inflammasomes. |
format | Online Article Text |
id | pubmed-8667020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-86670202021-12-14 Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases Soriano-Teruel, Paula M. García‑Laínez, Guillermo Marco-Salvador, María Pardo, Julián Arias, Maykel DeFord, Christian Merfort, Irmgard Vicent, María J. Pelegrín, Pablo Sancho, Mónica Orzáez, Mar Cell Death Dis Article The ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The formation of ASC specks, initiated by different inflammasome receptors, promotes the recruitment and activation of procaspase-1, thereby triggering pyroptotic inflammatory cell death and pro-inflammatory cytokine release. Here we describe MM01 as the first-in-class small-molecule inhibitor of ASC that interferes with ASC speck formation. MM01 inhibition of ASC oligomerization prevents activation of procaspase-1 in vitro and inhibits the activation of different ASC-dependent inflammasomes in cell lines and primary cultures. Furthermore, MM01 inhibits inflammation in vivo in a mouse model of inflammasome-induced peritonitis. Overall, we highlight MM01 as a novel broad-spectrum inflammasome inhibitor for the potential treatment of multifactorial diseases involving the dysregulation of multiple inflammasomes. Nature Publishing Group UK 2021-12-13 /pmc/articles/PMC8667020/ /pubmed/34903717 http://dx.doi.org/10.1038/s41419-021-04420-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Soriano-Teruel, Paula M. García‑Laínez, Guillermo Marco-Salvador, María Pardo, Julián Arias, Maykel DeFord, Christian Merfort, Irmgard Vicent, María J. Pelegrín, Pablo Sancho, Mónica Orzáez, Mar Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases |
title | Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases |
title_full | Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases |
title_fullStr | Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases |
title_full_unstemmed | Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases |
title_short | Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases |
title_sort | identification of an asc oligomerization inhibitor for the treatment of inflammatory diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667020/ https://www.ncbi.nlm.nih.gov/pubmed/34903717 http://dx.doi.org/10.1038/s41419-021-04420-1 |
work_keys_str_mv | AT sorianoteruelpaulam identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT garcialainezguillermo identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT marcosalvadormaria identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT pardojulian identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT ariasmaykel identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT defordchristian identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT merfortirmgard identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT vicentmariaj identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT pelegrinpablo identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT sanchomonica identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases AT orzaezmar identificationofanascoligomerizationinhibitorforthetreatmentofinflammatorydiseases |